Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.53 |
| ▸ | APEX1 | P27695 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | BCL6 | P41182 | 1/20 | 0.49 |
| ▸ | BCOR | Q6W2J9 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24430209 | 0.84 | MAPT (1.00) | MAPTKDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL20777365 | 0.84 | MAPT (0.68) | MAPTKDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL22425076 | 0.82 | MAPT (0.74) | MAPTKDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL24430188 | 0.80 | MAPT (0.62) | MAPTKDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL24430166 | 0.80 | MAPT (0.60) | MAPTKDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL20777328 | 0.79 | MAPT (0.75) | MAPTKDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL16088699 | 0.78 | MAPT (0.59) | MAPTKDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL10175685 | 0.78 | MAPT (0.65) | MAPTKDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL22425250 | 0.78 | MAPT (0.65) | MAPTKDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL20772687 | 0.77 | BCL6 (0.57) | MAPTKDM4EALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230366033-A1 | METHODS FOR TREATING CANCERS WITH INHIBITORS TARGETING THE ROLE OF GRB2 IN DNA REPAIR | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-11-16 | — | — | US | disclosed |
| US-20220151991-A1 | SMALL MOLECULE GRB2 STABILIZERS FOR RAS MAP KINASE INHIBITION | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-05-19 | — | — | US | disclosed |
| WO-2020186202-A1 | SMALL MOLECULE GRB2 STABILIZERS FOR RAS MAP KINASE INHIBITION | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220151991-A1 | SMALL MOLECULE GRB2 STABILIZERS FOR RAS MAP KINASE INHIBITION | GRB2, KRAS, HRAS | MAPT 3372/4885KDM4E 2747/4885ALDH1A1 3816/4885 |
| US-20230366033-A1 | METHODS FOR TREATING CANCERS WITH INHIBITORS TARGETING THE ROLE OF GRB2 IN DNA REPAIR | GRB2, RAD51, MRE11 | MAPT 4193/4885KDM4E 1900/4885ALDH1A1 3059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.